Added to YB: 2025-09-22
Pitch date: 2025-06-30
SKYE [neutral]
Skye Bioscience, Inc.
-73.48%
current return
Author Info
No bio for this author
Company Info
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases.
Market Cap
$45.2M
Pitch Price
$4.11
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.19
P/E
-1.13
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Platinum International Health Sciences Fund Portfolio Holding: Skye Bioscience, Inc.
SKYE (holding update): Developing nimacimab (anti-CB1 antibody) for weight loss in Phase 2 mono & combo w/ Wegovy. Mouse data shows weight loss + lean mass preservation. Key advantage: antibody doesn't cross blood-brain barrier, avoiding CNS side effects of prior small molecules. Clinical data imminent.
Read full article (1 min)